STAT

Opinion: Where was differential pricing at the WHO Fair Pricing Forum?

The largest elements missing from the issue of drug pricing are a basis of trust between industry, governments, and patient organizations and a belief that a joint resolution of the…
Source: FABRICE COFFRINI/AFP/Getty Images

Access to pricey prescription drugs has become a topic of focused attention for the World Health Organization, governments of middle- and lower-income countries, nongovernmental aid organizations, patient activists, and others. Many of these gathered at this month’s Fair Pricing Forum in Johannesburg, South Africa, which was sponsored by the WHO.

The invitation-only meeting, which was closed to the media, provided a venue for representatives of governments and nongovernmental organizations, academics, experts, and leaders from the pharmaceutical industry to address concerns about fair pricing and access to pharmaceuticals, especially in middle- and low-income countries.

I had the

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks